BOSTON, MA (March 1, 2021) — Valo Health LLC (Valo), the technology company that is using human-centric data and machine learning computation to transform and accelerate the drug discovery and development process, announced today that its CEO and founder, David Berry, will present at the following investor conferences in March:
Event: Barclays Global Healthcare Conference
Date/Time: Tuesday, March 9, 2021 at 8:00 a.m. EST
Event: Oppenheimer’s 31st Annual Healthcare Conference
Date/Time: Tuesday, March 16, 2021 8:40 a.m. EST
Investors: Graeme Bell, Chief Financial Officer
Jennifer Hanley, VP Corporate Communications
Valo Health, LLC (Valo) is a technology company that is using human-centric data and machine learning computation to transform the drug discovery and development process. As a digitally native company, Valo is the first to fully integrate human-centric data across the entire drug development lifecycle into a single unified architecture, thereby accelerating the discovery and development of life-changing drugs while simultaneously reducing the cost, time, and failure rate. The company’s Opal Computational PlatformTM, a fully integrated, computational, end-to-end drug development platform, offers a unique approach to therapeutic development that enables Valo to advance a robust pipeline of candidates across cardiovascular disease, oncology, and neurodegeneration. Founded by Flagship Pioneering and headquartered in Boston, MA, Valo has offices in Lexington, MA, San Francisco, CA, Princeton, NJ, and in Branford, CT. To learn more, visit www.valohealth.com.